MRIA9 is a Selective Salt-Inducible Kinase Inhibitor. MRIA9 showed dual SIK/PAK activity and excellent selectivity over other kinases. MRIA9 sensitizes ovarian cancer cells to treatment with the mitotic agent paclitaxel, confirming earlier data from genetic knockdown studies and suggesting a combination therapy with SIK inhibitors and paclitaxel for the treatment of paclitaxel-resistant ovarian cancer.
MedKoo Cat#: 464782
Name: MRIA9
CAS#: 2750707-05-0
Chemical Formula: C24H22ClFN6O3
Exact Mass: 496.1426
Molecular Weight: 496.93
Elemental Analysis: C, 58.01; H, 4.46; Cl, 7.13; F, 3.82; N, 16.91; O, 9.66
The following data is based on the product molecular weight 496.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
